First Trust Advisors’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$243K Buy
+4,273
New +$249K ﹤0.01% 2579
2025
Q1
– Sell
-123,568
Closed -$10.1M – 2600
2024
Q4
$10.1M Buy
123,568
+5,704
+5% +$566K 0.01% 1053
2024
Q3
$13.5M Buy
117,864
+38,938
+49% +$3.51M 0.01% 946
2024
Q2
$5.96M Buy
78,926
+15,100
+24% +$1.03M 0.01% 1193
2024
Q1
$4.36M Sell
63,826
-13,810
-18% -$956K ﹤0.01% 1370
2023
Q4
$4.88M Buy
77,636
+44,923
+137% +$2.33M 0.01% 1277
2023
Q3
$1.67M Sell
32,713
-2,691
-8% -$133K ﹤0.01% 1758
2023
Q2
$1.77M Sell
35,404
-1,806
-5% -$85.6K ﹤0.01% 1777
2023
Q1
$1.39M Buy
37,210
+16,749
+82% +$710K ﹤0.01% 1851
2022
Q4
$981K Buy
+20,461
New +$803K ﹤0.01% 1967

Other funds holding PCVX

First Trust Advisors's PCVX Position: Q3 2026 in Review

First Trust Advisors opened a new position in Vaxcyte (PCVX) in Q3 2026: 4,273 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #2579 among its holdings. This is a return to the name: First Trust Advisors previously reported a position in PCVX as recently as Q4 2024.

First Trust Advisors first reported a position in PCVX in Q4 2022 and has held it in 10 quarters since. The position peaked at $13.5M in Q3 2024. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • First Trust Advisors held 4,273 shares of Vaxcyte worth $243K as of Q3 2026.
  • Vaxcyte was a new First Trust Advisors position in Q3 2026.
  • Vaxcyte made up ﹤0.01% of First Trust Advisors's portfolio in Q3 2026, its #2579 holding.
  • First Trust Advisors first reported a position in Vaxcyte in Q4 2022 and has held it in 10 quarters since.
  • First Trust Advisors's Vaxcyte position peaked at $13.5M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on First Trust Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.